EQUITY RESEARCH

RBC Capital Markets

RBC Capital Markets, LLC
Adnan Butt (Analyst)
(415) 633-8588
adnan.butt@rbccm.com
John Chung (Associate)
(415) 633-8620
john.chung@rbccm.com
Jeffrey Takimoto (Associate)
(415) 633-8538
jeffrey.takimoto@rbccm.com

August 14, 2014

SCYNEXIS Inc.

Approaching Phase II start; should start producing results in 2015

Our view: 2Q results show sufficient cash and company is on track to start Phase II (oral) and Phase I (i.v.) studies.

Key points:

SCY-078 is on track to start a Phase II with the oral and a Phase I with the i.v. form with data from both studies expected starting 2015. The opportunity is life-threatening, fungal infections, especially those with resistance to current treatments. There is little competition and SCY-078 benefits from both the GAIN Act and FDA's QIDP designation, something well established for antibiotics. Shares have been volatile given the perceived distance to catalytic events, however, with trials starting, updates and data expected, and potentially plans for further/pivotal development in 2015, we continue to find SCYX an under appreciated opportunity. In our view, current levels are compelling with cash of ~$38M and an enterprise value of a mere ~$20M based on no debt and the current market cap.

- **2Q:14 results vs. expectations**. Revenues and expenses were slightly higher than forecast and ended with ~$38M in cash (~$4.52/ share).
- **2014 (and beyond) guidance**. We believe cash is sufficient into 2016.
- **Changes to our estimates** are modest and largely reflect 2Q results.

Key updates.

- **SCY-078 Phase II oral for invasive candidiasis**. The Phase II study comparing SCY-078 to micafungin and where possible to fluconazole is expected to begin by YE:14. We believe updates are likely in 2015 with final data likely by 1Q:16 or sooner. The study is open label and key in demonstrating feasibility, safety and efficacy of moving patients to oral SCY-078.
- **SCY-078 Phase I i.v. for invasive fungal infections**. The intravenous form of SCY-078 could begin a Phase I study in 1H:15 and report data. The key here is availability as ideally the patient is started on the i.v. and then transition to an oral form. The oral form has QIDP designation and we expect the same of the oral form.
- **SCY-078 future development plans**. A key question is the potential to start a Phase II/ III in a select, resistant patient population once data from the Phase II oral and Phase I i.v. SCY-078 studies are available. Clarity on this front is also possible in 2015.
- **Business development possibilities remain**. SCYX generates revenues and has a non-core pipeline, including cyclophilin inhibitors, which could be out-licensed opportunistically.

Upcoming news flow.

- SCY-078 Phase II oral data in mid-2015 and 1Q:16.
- SCY-078 Phase I i.v. data in 1H/Mid-2015.

Outperform

Speculative Risk

NASDAQ: SCYX; USD 6.82

Price Target USD 17.00

WHAT'S INSIDE

☐ Rating/Risk Change	☐ Price Target Change
☐ In-Depth Report	☑ Est. Change
☐ Preview	☐ News Analysis

Scenario Analysis*



*Implied Total Returns

Key Statistics

Shares O/S (MM):	9.7	Market Cap (MM):	66
Dividend:	0.00	Yield:	0.0%

RBC Estimates

FY Dec	2013A	2014E	2015E	2016E
Revenue	16.9	18.3	18.0	18.1
Prev.		17.5	17.1	17.2
EPS, Ops Diluted	(6.84)	(3.83)	(2.23)	(2.01)
Prev.		(1.77)	(2.33)	(2.00)
P/E	NM	NM	NM	NM

Revenue	**Q1**	**Q2**	**Q3**	**Q4**
2014	4.7A	4.6A	4.5E	4.5E
Prev.		4.3E	4.3E	4.3E
2015	4.5E	4.5E	4.5E	4.5E
Prev.	4.3E	4.3E	4.3E	4.3E
EPS, Ops Diluted				
2014	(3.65)A	(0.98)A	(0.42)E	(0.58)E
Prev.		(0.39)E	(0.45)E	(0.55)E
2015	(0.50)E	(0.53)E	(0.56)E	(0.64)E
Prev.	(0.53)E	(0.56)E	(0.58)E	(0.66)E

EPS, Ops Diluted: Basic shares used when EPS are negative.
All values in USD unless otherwise noted.

Priced as of prior trading day's market close, EST (unless otherwise noted).

For Required Conflicts Disclosures, see Page 7

Target/Upside/Downside Scenarios

Exhibit 1: SCYNEXIS Inc.



Source: Bloomberg and RBC Capital Markets estimates for Upside/Downside/Target

Target price/ base case

We value SCYX at $17 per share, which includes US and ROW sales of SCY-078. We assign a probability of success of 65% and a value of ~$6 per share to the US and $11 per share to the ROW opportunity. We assume a US launch in 2019 and an ROW launch in 2020. Currently, we assume that SCYX will sell SCY-078 in the US and a partner will commercialize these compounds outside the US. We forecast peak SCY-078 sales of $300-400MM in the US and $1.0-1.4B in the ROW.

Upside scenario

Our upside scenario includes ~$16 per share in value for the US opportunity and ~$18 per share in value for the ROW opportunity. We forecast peak SCY-078 sales of $600-700MM in the US and $1.7B-$2B in the ROW. We assign SCY-078 a 60% probability of success, a discount rate of 15%, and use a terminal growth rate of -50%.

Downside scenario

Our downside scenario assumes that SCY-078 may not be successful clinically or commercially either because efficacy against resistant organisms was not borne out or it was not long lasting or an unexpected adverse event was seen. Under such a scenario shares would trade at roughly cash per share which is currently ~$5.

Investment summary

Scynexis' (SCYX) SCY-078 treats systemic fungal infections via a new mechanism of action that attacks the fungal cell wall, a validated target. These infections are serious, have high rates of mortality, and rates of resistance to current drugs are rising. All currently available drugs have limitations, which allow SCY-078 to generate an attractive value proposition. The worldwide market for systemic anti-fungals is nearly $4B. Roughly 600,000 patients are identified with invasive fungal infections and an even higher number is treated. Phase I studies are completed for the oral version and in vitro and in vivo data shows activity in organisms both susceptible and resistant to currently approved drugs. Next up is a Phase II for the oral and a Phase I for the intravenous form with data in 2015. A Phase II/III study in resistant patients could start in 2016 and potentially provide a more rapid path to the market. SCYX essentially owns all rights to SCY-078, which is patent protected through 2030, as well as to its anti-fungal pipeline. This leaves SCYX free to commercialize the products itself, partner on a global or regional basis, and/or sell the company.

Potential catalysts for SCYX shares

- **Phase II data for oral SCY-078 in 2015.** Important catalyst as this will be the first time SCY-078 will be used in human patients.
- **Phase I data for intravenous SCY-078 in 2015.** Important as an intravenous does not yet exist and is needed to maximize the value of SCY-078 franchise.
- **Phase II/III trial design in 2015/2016.** A sign off from the FDA could determine the pace and potential path to the market.
- **Phase II/III trial start in 2016 and data by YE:17/ early 2018.** A Phase II/III study in drug resistant patients could be the first proof that SCY-078 can achieve in patients what it is designed to do and has shown in in vitro and in vivo models.
- **Business development activities in 2014/2015.** Non-core pipeline assets and even SCY-078 could be partnered opportunistically raising non-dilutive capital.

Risks to our investment thesis

- **Clinical studies for oral and intravenous SCY-078 could fail**. Expectations are based on pre-clinical and Phase I data and human studies could show a lack of efficacy or emergence of resistance.
- **Merck returned rights for SCY-078 back to SCYX**. This raises the question of whether MRK saw anything in SCY-078's clinical or commercial profile that was lacking.
- **Sales ramp of SCY-078 could lag expectations** unless rates of resistance continue to rise.
- **SCYX could fail to find a partner** outside the US for SCY-078.
- **Timelines are rapid and any delays could disappoint investors**.

Exhibit 2: 2Q14 Actual vs. RBC estimates

(in MM; except per share)	2Q:14A	Est.	Var.
Revenue:			
SCY-078			
Other Revenue	4.6	4.3	0.4
Total Revenue	4.6	4.3	0.4
Operating expenses:			
Cost of Other Revenue	4.2	4.1	0.1
R&D	1.8	2.3	(0.4)
SG&A	2.3	1.3	1.0
Other	(0.2)		(0.2)
Total Expenses	8.1	7.6	0.5
Operating Expense (income)	(3.5)	(3.4)	(0.1)
Other:			
Amortization of deferred financing cost and debt discount	0.2		0.2
Interest expense for beneficial conversion feature	0.0		0.0
Interest expense-related party			
Interest expense		(0.0)	
Derivative fair value adjustment	(7.3)		(7.3)
Other income	1.4	0.1	
Income before Tax	2.2	(3.3)	5.6
Taxes			
Net income (loss)	2.2	(3.3)	5.6
EPS, Basic (GAAP)	$0.38	($0.39)	$0.77
EPS, Diluted (GAAP)	($0.98)	($0.37)	($0.60)
Shares outstanding, Basic	5.2	8.5	(3.4)
Shares outstanding, Diluted	5.5	9.0	(3.5)

Source: Company reports and RBC Capital Markets estimates

Exhibit 3: News Flow

Timing	Expected News Flow	Program
YE:14	Initiate Phase II with oral SCY-078	SCY-078
Late 2014/ early 2015	Request QIDP designation for i.v. SCY-078	SCY-078
2014/2015	Potential pipeline related business development	
1H:15	Initiate Phase I study with i.v. SCY-078	SCY-078
1H:15/ mid-2015	Phase I intravenous SCY-078 results	SCY-078
2015	Phase II update from oral SCY-078 step down study	SCY-078
1Q:16	Phase II results from oral SCY-078 step down study	SCY-078
2016	Initiate Phase II/III i.v. to oral SCY-078 in relapsed/ refractory patients	SCY-078
YE:2016/ early 2017	Initiate Phase III study for i.v. to oral SCY-078 in 1st line patients	SCY-078
Late 2017/ early 2018	Phase II/III i.v. to oral data	SCY-078
2018	Potential NDA for SCY-078	SCY-078
YE:18/ 2019	Potential accelerated approval	SCY-078

Source: Company reports and RBC Capital Markets estimates

Exhibit 4: Pipeline

Product	Mechanism	Stage	Indication
SCY-078	1,3 beta fl glucan synthesis inhibitor	Phase II anticipated with oral; Phase I with intravenous anticipated	Invasive fungal infections caused by Candida and Aspergillus species
SCY-635	Cyclophilin inhibitor	Phase IIa	Hepatitis C Virus (HCV)
SCYX-7158	Anti-parasitic	Phase I	Human African Trypanosomiasis (Sleeping sickness)
SCY-641	Cyclophilin inhibitor	Pre-Clinical	Dry Eye disease

Source: Company reports

Valuation

We value SCYX at $17 per share, which includes US and ROW sales of SCY-078. We assign a probability of success of 65% and a value of ~$6 per share to the US and $11 per share to the ROW opportunity. We assume a US launch in 2019 and an ROW launch in 2020. Currently, we assume that SCYX will sell SCY-078 in the US and a partner will commercialize these compounds outside the US. We forecast peak SCY-078 sales of $300-400MM in the US and $1.0-1.4B in the ROW. We currently assign no additional value to the earlier stage pipeline. Finally, we assume product sales extend into 2030 and include a terminal value based on a terminal growth rate of -50% and a discount rate of 15%.

Price target impediments

Our price target is dependent solely on the clinical, regulatory and commercial success of SCY-078. A Phase II study for SCY-078 is expected in 2014 and data expected in 2015. Failure to demonstrate efficacy or safety in the study would be a significant setback. Furthermore, any setbacks in regulatory approvals in the US or EU, delay in launch, failure to secure a partnership outside the US for SCY-078, increased competition or other limitations to the market potential of these products either due to better efficacy and/or safety outcomes or pricing pressure due to the availability of generic drugs for glaucoma, could negatively impact our valuation.

Company description

SCYNEXIS Inc. (SCYX) SCY-078 treats systemic fungal infections via a new mechanism of action that targets the fungal cell wall. These infections are serious, kill patients, and rates of resistance to current drugs are rising, while all currently available drugs have their limitations, which is the value proposition for SCY-078. The worldwide market for systemic anti-fungals is nearly $4B. Roughly 600,000 patients are identified with invasive fungal infections and an even higher number is treated. Phase I studies are completed for the oral version and in vitro and in vivo data shows activity in organisms both susceptible and resistant to currently approved drugs. Next up is a Phase II for the oral and a Phase I for the intravenous forms with data in 2015. A Phase II/III study in resistant patients could start in 2016 and potentially provide a more rapid path to the market. SCYX essentially owns all rights to SCY-078, which is patent protected through 2030, as well as to its anti-fungal portfolio. This leaves SCYX free to commercialize the products itself, partner on a global or regional basis, and/or sell the company.

Scynexis - Income Statement

FYE December 31

Adnan Butt (415) 633-8588

Adnan.Butt@rbccm.com

(in MM; except per share)	2013A	1Q:14A	2Q:14A	3Q:14E	4Q:14E	2014E	1Q:15E	2Q:15E	3Q:15E	4Q:15E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
Revenue:																			
SCY-078															24.6	46.1	68.4	91.5	115.6
Other Revenue	9.6	4.7	4.6	4.5	4.5	18.3	4.5	4.5	4.5	4.5	18.0	18.1	18.2	18.3	18.4	18.5	18.6	18.7	18.8
Total Revenue	16.9	4.7	4.6	4.5	4.5	18.3	4.5	4.5	4.5	4.5	18.0	18.1	18.2	18.3	43.0	73.1	108.7	145.7	184.2
Operating expenses:																			
Cost of Other Revenue	16.3	4.0	4.2	4.1	4.1	16.2	4.1	4.1	4.1	4.1	16.2	17.5	17.6	17.7	17.8	17.9	18.0	18.1	18.2
R&D	4.4	1.3	1.8	2.8	4.1	10.0	3.3	3.5	3.8	4.5	15.0	20.0	30.0	35.0	25.0	22.5	25.0	27.5	30.0
SG&A	4.4	1.2	2.3	1.3	1.3	6.0	1.5	1.5	1.5	1.5	8.0	8.5	9.0	10.0	22.5	28.8	30.0	32.5	33.1
Other	(1.0)		(0.2)			(0.2)													
Total Expenses	24.1	6.5	8.1	8.1	9.4	32.0	8.8	9.1	9.3	10.1	37.2	46.0	56.6	62.7	67.8	73.8	79.8	87.3	92.9
Operating Expense (income)	(7.2)	(1.8)	(3.5)	(3.6)	(4.9)	(13.7)	(4.3)	(4.6)	(4.8)	(5.6)	(19.2)	(27.9)	(38.4)	(44.4)	(24.7)	(0.7)	28.9	58.5	91.3
Other:																			
Amortization of deferred financing cost and debt discount	3.5	0.5	0.2			0.8													
Interest expense for beneficial conversion feature	10.8		0.0			0.0													
Interest expense-related party	0.9																		
Interest expense	0.2	0.0				0.0													
Derivative fair value adjustment	7.9	(2.8)	(7.3)			(10.1)													
Other income		0.0	1.4	(0.1)	(0.1)	1.3	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)	(0.4)	(0.6)	(0.8)
Income before Tax	(30.5)	0.4	2.2	(3.6)	(5.0)	(21.7)	(4.4)	(4.6)	(4.9)	(5.6)	(19.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	28.5	57.9	90.5
Taxes																	9.7	19.7	30.8
Net income (loss)	(30.5)	0.4	2.2	(3.6)	(5.0)	(21.7)	(4.4)	(4.6)	(4.9)	(5.6)	(19.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	18.8	38.2	59.7
Net loss to common stockholders	(46.8)	(1.2)	2.0	(3.6)	(5.0)	(21.7)	(4.4)	(4.6)	(4.9)	(5.6)	(19.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	18.8	38.2	59.7
Derivative fair value adjustment		(2.8)	(7.3)	-	-	(10.1)	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss to common stockholders (diluted)		(4.0)	(5.3)	(3.6)	(5.0)	(31.7)	(4.4)	(4.6)	(4.9)	(5.6)	(19.4)	(28.0)	(38.5)	(44.5)	(24.8)	(0.9)	18.8	38.2	59.7
EPS, Basic (GAAP)	($6.84)	($3.65)	$0.38	($0.42)	($0.58)	($3.83)	($0.50)	($0.53)	($0.56)	($0.64)	($2.23)	($2.01)	($2.71)	($3.07)	($1.25)	($0.04)	$0.91	$1.82	$2.79
EPS, Diluted (GAAP)	($5.61)	($6.57)	($0.98)	($0.39)	($0.53)	($5.14)	($0.46)	($0.49)	($0.51)	($0.59)	($2.04)	($1.89)	($2.54)	($2.86)	($1.18)	($0.04)	$0.85	$1.69	$2.58
Shares outstanding, Basic	6.8	0.3	5.2	8.5	8.6	5.7	8.6	8.7	8.7	8.8	8.7	13.9	14.2	14.5	19.8	20.2	20.6	21.0	21.4
Shares outstanding, Diluted	8.3	0.6	5.5	9.3	9.4	6.2	9.4	9.5	9.5	9.6	9.5	14.8	15.2	15.6	21.0	21.5	22.0	22.6	23.1
Operating Ratios	2013A	1Q:14A	2Q:14A	3Q:14E	4Q:14E	2014E	1Q:15E	2Q:15E	3Q:15E	4Q:15E	2015E	2016E	2017E	2018E	2019E	2020E	2021E	2022E	2023E
COGS															10.0%	10.0%	10.0%	10.0%	10.0%
Gross Margin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	90.0%	90.0%	90.0%	90.0%	90.0%
R&D	25.9%	28.1%	39.3%	61.1%	91.3%	54.5%	72.2%	77.8%	83.3%	100.0%	83.3%	110.5%	164.8%	191.3%	58.1%	30.8%	23.0%	18.9%	16.3%
SG&A	26.0%	25.6%	48.6%	27.8%	27.8%	32.5%	33.3%	33.3%	33.3%	33.3%	44.4%	47.0%	49.5%	54.6%	52.3%	39.3%	27.6%	22.3%	18.0%
Operating Margin	-42.7%	-37.9%	-74.3%	-78.9%	-109.0%	-74.6%	-95.6%	-101.1%	-106.7%	-123.3%	-106.7%	-154.1%	-211.0%	-242.6%	-57.4%	-0.9%	26.6%	40.1%	49.6%
Taxes	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%	34.0%
Net Margin	-180.7%	8.8%	48.1%	-80.0%	-110.2%	-118.1%	-96.7%	-102.2%	-107.8%	-124.4%	-107.8%	-154.7%	-211.5%	-243.2%	-57.7%	-1.2%	17.3%	26.2%	32.4%

Source: Company reports and RBC Capital Markets estimates.

RBC Capital Markets

Required disclosures

Conflicts disclosures

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors, including total revenues of the member companies of RBC Capital Markets and its affiliates, a portion of which are or have been generated by investment banking activities of the member companies of RBC Capital Markets and its affiliates.

Please note that current conflicts disclosures may differ from those as of the publication date on, and as set forth in, this report. To access current conflicts disclosures, clients should refer to https://www.rbccm.com/GLDisclosure/PublicWeb/DisclosureLookup.aspx?entityId=1 or send a request to RBC CM Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7.

A member company of RBC Capital Markets or one of its affiliates managed or co-managed a public offering of securities for SCYNEXIS Inc. in the past 12 months.

A member company of RBC Capital Markets or one of its affiliates received compensation for investment banking services from SCYNEXIS Inc. in the past 12 months.

RBC Capital Markets, LLC makes a market in the securities of SCYNEXIS Inc..

RBC Capital Markets has provided SCYNEXIS Inc. with investment banking services in the past 12 months.

Explanation of RBC Capital Markets Equity rating system

An analyst's 'sector' is the universe of companies for which the analyst provides research coverage. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12 months relative to the analyst's sector average. Although RBC Capital Markets' ratings of Top Pick (TP)/Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis.

Ratings

Top Pick (TP): Represents analyst's best idea in the sector; expected to provide significant absolute total return over 12 months with a favorable risk-reward ratio.

Outperform (O): Expected to materially outperform sector average over 12 months.

Sector Perform (SP): Returns expected to be in line with sector average over 12 months.

Underperform (U): Returns expected to be materially below sector average over 12 months.

Risk Rating

As of March 31, 2013, RBC Capital Markets suspends its Average and Above Average risk ratings. The **Speculative** risk rating reflects a security's lower level of financial or operating predictability, illiquid share trading volumes, high balance sheet leverage, or limited operating history that result in a higher expectation of financial and/or stock price volatility.

Distribution of ratings

For the purpose of ratings distributions, regulatory rules require member firms to assign ratings to one of three rating categories - Buy, Hold/Neutral, or Sell - regardless of a firm's own rating categories. Although RBC Capital Markets' ratings of Top Pick(TP)/Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis (as described below).

Distribution of ratings
RBC Capital Markets, Equity Research
As of 30-Jun-2014

			Investment Banking Serv./Past 12 Mos.	
Rating	Count	Percent	Count	Percent
BUY [Top Pick & Outperform]	845	53.24	299	35.38
HOLD [Sector Perform]	658	41.46	159	24.16
SELL [Underperform]	84	5.29	10	11.90



References to a Recommended List in the recommendation history chart may include one or more recommended lists or model portfolios maintained by RBC Wealth Management or one of its affiliates. RBC Wealth Management recommended lists include a former list called the Prime Opportunity List (RL 3), the Guided Portfolio: Prime Income (RL 6), the Guided Portfolio: Large Cap (RL 7), the Guided Portfolio: Dividend Growth (RL 8), the Guided Portfolio: Midcap 111 (RL 9), the Guided Portfolio: ADR (RL 10), and the Guided Portfolio: Global Equity (U.S.) (RL 11). RBC Capital Markets recommended lists include the Strategy Focus List and the Fundamental Equity Weightings (FEW) portfolios. The abbreviation 'RL On' means the date a security was placed on a Recommended List. The abbreviation 'RL Off' means the date a security was removed from a Recommended List.

Equity valuation and risks

For valuation methods used to determine, and risks that may impede achievement of, price targets for covered companies, please see the most recent company-specific research report at https://www.rbcinsight.com or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7.

Conflicts policy

RBC Capital Markets Policy for Managing Conflicts of Interest in Relation to Investment Research is available from us on request. To access our current policy, clients should refer to
https://www.rbccm.com/global/file-414164.pdf
or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7. We reserve the right to amend or supplement this policy at any time.

Dissemination of research and short-term trade ideas

RBC Capital Markets endeavours to make all reasonable efforts to provide research simultaneously to all eligible clients, having regard to local time zones in overseas jurisdictions. Subject to any applicable regulatory considerations, "eligible clients" may include RBC Capital Markets institutional clients globally, the retail divisions of RBC Dominion Securities Inc. and RBC Capital Markets LLC, and affiliates. RBC Capital Markets' equity research is posted to our proprietary websites to ensure eligible clients receive coverage initiations and changes in rating, targets and opinions in a timely manner. Additional distribution may be done by the sales personnel via email, fax or regular mail. Clients may also receive our research via third party vendors. Please contact your investment advisor or institutional salesperson for more information regarding RBC Capital Markets research. RBC Capital Markets also provides eligible clients with access to SPARC on its proprietary INSIGHT website. SPARC contains market color and commentary, and may also contain Short-Term Trade Ideas regarding the securities of subject companies discussed in this or other research reports. SPARC may be accessed via the following hyperlink: https://www.rbcinsight.com. A Short-Term Trade Idea reflects the research analyst's directional view regarding the price of the security of a subject company in the coming days or weeks, based on market and trading events. A Short-Term Trade Idea may differ from the price targets and/or recommendations in our

published research reports reflecting the research analyst's views of the longer-term (one year) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. Thus, it is possible that the security of a subject company that is considered a long-term 'Sector Perform' or even an 'Underperform' might be a short-term buying opportunity as a result of temporary selling pressure in the market; conversely, the security of a subject company that is rated a long-term 'Outperform' could be considered susceptible to a short-term downward price correction. Short-Term Trade Ideas are not ratings, nor are they part of any ratings system, and RBC Capital Markets generally does not intend, nor undertakes any obligation, to maintain or update Short-Term Trade Ideas. Short-Term Trade Ideas discussed in SPARC may not be suitable for all investors and have not been tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any Short-Term Trade Ideas discussed therein.

Analyst certification

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by RBC. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Disclaimer

RBC Capital Markets is the business name used by certain branches and subsidiaries of the Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets, LLC, RBC Europe Limited, RBC Capital Markets (Hong Kong) Limited, Royal Bank of Canada, Hong Kong Branch and Royal Bank of Canada, Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. RBC Capital Markets may be restricted from publishing research reports, from time to time, due to regulatory restrictions and/or internal compliance policies. If this is the case, the latest published research reports available to clients may not reflect recent material changes in the applicable industry and/or applicable subject companies. RBC Capital Markets research reports are current only as of the date set forth on the research reports. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior consent of RBC Capital Markets.

Additional information is available on request.

To U.S. Residents:
This publication has been approved by RBC Capital Markets, LLC (member FINRA, NYSE, SIPC), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets, LLC.

To Canadian Residents:
This publication has been approved by RBC Dominion Securities Inc.(member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

To U.K. Residents:
This publication has been approved by RBC Europe Limited ('RBCEL') which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ('FCA') and the Prudential Regulation Authority, in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. However, targeted distribution may be made to selected retail clients of RBC and its affiliates. RBCEL accepts responsibility for this report and its dissemination in the United Kingdom.

To Persons Receiving This Advice in Australia:
This material has been distributed in Australia by Royal Bank of Canada - Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on

this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section 761G of the Corporations Act.

To Hong Kong Residents:

This publication is distributed in Hong Kong by RBC Investment Services (Asia) Limited, RBC Investment Management (Asia) Limited and RBC Capital Markets (Hong Kong) Limited, licensed corporations under the Securities and Futures Ordinance or, by the Royal Bank of Canada, Hong Kong Branch, a registered institution under the Securities and Futures Ordinance. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact RBC Investment Services (Asia) Limited, RBC Investment Management (Asia) Limited, RBC Capital Markets (Hong Kong) Limited or Royal Bank of Canada, Hong Kong Branch at 17/Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (telephone number is 2848-1388).

To Singapore Residents:

This publication is distributed in Singapore by the Royal Bank of Canada, Singapore Branch and Royal Bank of Canada (Asia) Limited, registered entities granted offshore bank and merchant bank status by the Monetary Authority of Singapore, respectively. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is not indicative of future performance. If you have any questions related to this publication, please contact the Royal Bank of Canada, Singapore Branch or Royal Bank of Canada (Asia) Limited.

To Japanese Residents:

Unless otherwise exempted by Japanese law, this publication is distributed in Japan by or through RBC Capital Markets (Japan) Ltd., a registered type one financial instruments firm and/or Royal Bank of Canada, Tokyo Branch, a licensed foreign bank.

® Registered trademark of Royal Bank of Canada. RBC Capital Markets is a trademark of Royal Bank of Canada. Used under license.
Copyright © RBC Capital Markets, LLC 2014 - Member SIPC
Copyright © RBC Dominion Securities Inc. 2014 - Member CIPF
Copyright © RBC Europe Limited 2014
Copyright © Royal Bank of Canada 2014
All rights reserved